Merck, Inc.
🇵🇭Philippines
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 78
- Registration Number
- NCT00770159
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 62
- Registration Number
- NCT00769418
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00768521
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00769132
MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: MK0633
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00768170
A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)
Phase 1
Completed
- Conditions
- Glaucoma
- Interventions
- Drug: INS117548Drug: Placebo
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 84
- Registration Number
- NCT00767793
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
Phase 2
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 813
- Registration Number
- NCT00767000
Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)
Phase 2
Terminated
- Conditions
- Alcoholism
- Interventions
- Drug: SCH 900435Drug: Placebo
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 141
- Registration Number
- NCT00764660
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 209
- Registration Number
- NCT00764946
Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)
Completed
- Conditions
- PruritusRhinitis, Allergic, SeasonalRhinitis, Allergic, PerennialUrticaria
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1003
- Registration Number
- NCT00762983
© Copyright 2025. All Rights Reserved by MedPath